Navigation Links
Positive Statistical Analysis from Synthetic Blood's Oxycyte,Traumatic Brain Injury Trial Indicates Achievement of Primary,Endpoint

COSTA MESA, Calif.--(BUSINESS WIRE)--May 15, 2007 - Synthetic Blood International, Inc. (OTCBB:SYBD) today announced positive data from a statistical analysis of its Phase IIa study with Oxycyte(TM) in patients with traumatic brain injury. In line with preliminary study results announced in December 2006, statistical results confirmed that the primary endpoint of increasing patients' oxygen tension levels compared with baseline was met. Data also show a decrease in patient glucose and lactate/pyruvate (LP) ratio, consistent with increased glucose metabolism. Patients in this trial were stabilized with either 50% or 100% oxygen. Data determined that results of both treatment arms were favorable, with statistically significant differences in some data between the two treatment arms.

"This analysis further validates our initial study findings that Oxycyte is more effective in increasing brain oxygen tension levels and impacting other brain chemistries that contribute to more favorable clinical outcomes in patients with traumatic brain injury, than breathing either 100% or 50% oxygen alone," said Robert Nicora, president and CEO. "Based on these positive results, we are working with Virginia Commonwealth University (VCU) to develop a protocol for a multicenter, controlled Phase IIb trial that could enroll up to 100 patients with traumatic brain injury. Researchers at VCU are drafting a manuscript with the Phase IIa TBI results to submit to a scientific journal.

"We continue active discussions with several sources for financing the Company," Mr. Nicora continued. "If we are successful in these discussions, the receipt of additional funding will enable us to move forward with our Phase IIb program and other development activities with Oxycyte, which include plans to initiate a cardiac ischemia study in an animal model."

Phase IIa Oxycyte Trial in Patients with Traumatic Brain Injury

In this open
'"/>




Page: 1 2 3

Related medicine technology :

1. Neose Announces Presentation of Positive Preclinical Data on GlycoPEGylated Factor VIIa at the XXI Congress of the International Society on Thrombosis and Haemostasis
2. Positive Aggrastat Results Featured in the Journal of the American College of Cardiology
3. Portola Pharmaceuticals Announces Positive Data from a Phase II Study of its Factor Xa Inhibitor at the XXI Congress of the International Society on Thrombosis and Haemostasis
4. Protox Announces Positive Clinical Data from Prostate Cancer Study
5. AM-Pharma Announces Positive Results of Phase IIa Clinical Trial with Alkaline Phosphatase For Ulcerative Colitis
6. Cougar Biotechnology Announces Presentation of Positive CB7630 Clinical Data at ESMO Conference
7. TransPharma Medical Announces Positive Results of Phase I Clinical Trials for Transdermal Delivery of hPTH (1-34) for Osteoporosis Treatment
8. Positive ZIO-201 Interim Phase II Sarcoma Data Presented at European Society for Medical Oncology
9. Cosmo Pharmaceuticals Reports Positive Preliminary Phase II/III Data with Rifamycin MMX in Infectious Diarrhea
10. Portola Pharmaceuticals Announces Positive Phase II EXPERT Results and Additional Oral and Poster Presentations at the XXI Congress of the International Society on Thrombosis and Haemostasis (ISTH)
11. Chi-Med Announces Positive Phase II Proof-of-Concept Data for HMPL-004 in Ulcerative Colitis
Post Your Comments:
(Date:9/19/2014)... DALLAS , Sept. 19, 2014 /PRNewswire-iReach/ ... Chinese Oxybutynin Hydrochloride Industry, 2009-2019 is a ... and Chinese Oxybutynin Hydrochloride industry. The report ... Hydrochloride including its classification, application and manufacturing ... China,s top manufacturers of Oxybutynin Hydrochloride listing ...
(Date:9/19/2014)... , September 19, 2014 ... ) has announced the addition of the ... report to their offering.      ... have been broadly classified into wide categories ... used for the treatment of different gynecological ...
(Date:9/19/2014)... , September 19, 2014 ... by Equipment (Cryotherapy, Heat, therapy, Hydrotherapy), Accessories (Posture Mirror, ... (Hospitals), Advanced technologies - Global Forecast to 2019" ... poised to reach $19,786.3 Million by 2019 from ... 6.8% from 2014 to 2019. Browse ...
Breaking Medicine Technology:Oxybutynin Hydrochloride Industry 2014-2019 Chinese Forecasts & Analysis 2Oxybutynin Hydrochloride Industry 2014-2019 Chinese Forecasts & Analysis 3Oxybutynin Hydrochloride Industry 2014-2019 Chinese Forecasts & Analysis 4Oxybutynin Hydrochloride Industry 2014-2019 Chinese Forecasts & Analysis 5Global Gynecological Devices Market 2014-2018: Key Vendors are Bayer, Boston Scientific, CooperSurgical, Ethicon, Hologic, Medtronic, Olympus and Stryker 2Global Gynecological Devices Market 2014-2018: Key Vendors are Bayer, Boston Scientific, CooperSurgical, Ethicon, Hologic, Medtronic, Olympus and Stryker 3Physiotherapy Equipment Market Worth $19,786.3 Million by 2019 2Physiotherapy Equipment Market Worth $19,786.3 Million by 2019 3Physiotherapy Equipment Market Worth $19,786.3 Million by 2019 4
... 17, 2011 Reportlinker.com announces that a ... its catalogue: Product ... Pipeline Strengthening the In-Vitro Diagnostics and Cardiovascular ... http://www.reportlinker.com/p0397058/Product-Pipeline-in-Medical-Equipment-Market---Robust-Pipeline-Strengthening-the-In-Vitro-Diagnostics-and-Cardiovascular-Devices-Market.html Product Pipeline in ...
... Ala., Feb. 17, 2011 SuccessEHS, a nationally recognized, ... EMR) software vendor, was recently named by the Arkansas ... in accordance with government health care initiatives. ... Arkansas REC are endowed by the Office of ...
Cached Medicine Technology:Reportlinker Adds Product Pipeline in Medical Equipment Market - Robust Pipeline Strengthening the In-Vitro Diagnostics and Cardiovascular Devices Market 2Arkansas REC Selects SuccessEHS as Preferred Vendor 2Arkansas REC Selects SuccessEHS as Preferred Vendor 3
(Date:9/22/2014)... FL (PRWEB) September 22, 2014 ... than 2,000 physicians, today Clearwater Clinical ... ClearSCOPE Endoscope Adaptor for smartphones. ClearSCOPE ... video from virtually any endoscope and smartphone. , ... adaptor in response to frustrations over the cost, ...
(Date:9/22/2014)... On Saturday, September 27, 2014, La Comunidad Hispana ... fair ¡Vive tu vida! Get Up! Get Moving!® This event ... health and wellness for people of all ages and all ... public, will be held at Anson B. Nixon Park, 100 ... pm. , “This is a wonderful event each year ...
(Date:9/22/2014)... Steven Reinberg HealthDay Reporter ... six-year study of people with type 2 diabetes found ... in preventing heart attacks, strokes and deaths. But intensive ... found. For the study, investigators followed nearly 8,500 ... had their blood pressure and blood sugar levels strictly ...
(Date:9/22/2014)... September 22, 2014 At the ... nonprofit Seafood Nutrition Partnership (SNP) announced the successful ... Healthy: A Cardiovascular Risk Reduction Program for Women. ... understand and mitigate their risk of heart disease ... Action, a plan for addressing significant global challenges ...
(Date:9/22/2014)... The Drive Against Domestic Violence ( ... Ben Talei, MD - a Beverly Hills Facial Plastic ... brothers have planned to drive across the country during ... raise funds and awareness for the National Coalition Against ... the American Academy of Facial Plastic & Reconstructive Surgery's ...
Breaking Medicine News(10 mins):Health News:ClearSCOPE 2.0 Endoscope Adaptor for Smartphones Announced; Endoscopic Video Capture Reinvented 2Health News:La Comunidad Hispana Presents Fourth Annual ¡Vive Tu Vida! Get Up! Get Moving!® Event 2Health News:La Comunidad Hispana Presents Fourth Annual ¡Vive Tu Vida! Get Up! Get Moving!® Event 3Health News:Tight Blood Sugar Control Doesn't Prevent Strokes in Diabetics: Study 2Health News:Tight Blood Sugar Control Doesn't Prevent Strokes in Diabetics: Study 3Health News:At 2014 Clinton Global Initiative Annual Meeting, Seafood Nutrition Partnership Announces Pilot Program to Reduce Women’s Heart Disease Risks 2Health News:At 2014 Clinton Global Initiative Annual Meeting, Seafood Nutrition Partnership Announces Pilot Program to Reduce Women’s Heart Disease Risks 3Health News:At 2014 Clinton Global Initiative Annual Meeting, Seafood Nutrition Partnership Announces Pilot Program to Reduce Women’s Heart Disease Risks 4Health News:FOX 5 News Story - Dr. Ben Talei a Beverly Hills Facial Plastic Surgeon organizes the Drive Against Domestic Violence & Botox-for-a-Cause as he Drives across the country 2Health News:FOX 5 News Story - Dr. Ben Talei a Beverly Hills Facial Plastic Surgeon organizes the Drive Against Domestic Violence & Botox-for-a-Cause as he Drives across the country 3
... Berger & Grossmann LLP is issuing the following statement regarding the Sunrise Senior Living, Inc. Securities Litigation. , , ... UNITED STATES DISTRICT COURT, ... INC. Master File, SECURITIES LITIGATION ... Relates to: All Cases, ...
... suggests, , , MONDAY, April 20 (HealthDay News) -- Want to live ... manage your stress. , A new study found that those were ... 100, and longevity is thought to run in families. , "We ... set the children of centenarians apart from other people the same ...
... HOLLYWOOD, Calif., April 20 IPC The Hospitalist ... hospitalist physician group practice company, announced today that it will ... on May 4, 2009, after the market close.A conference call ... (2:00 p.m. PT) on May 4, 2009 and will be ...
... "With Hurricanes Katrina, Rita and Ike we ... and healthcare providers navigate through chaos created by ... Davies, M.D., a seasoned critical care physician and ... which enable communication between patients, their physicians, hospitals ...
... with Picoplatin as Second-Line Therapy for Small Cell Lung ... Poniard Pharmaceuticals, Inc. (Nasdaq: PARD ), a ... of its Phase 2 clinical trial of picoplatin in ... were published in the April 20, 2009, print ...
... 20, 2009 Forest Laboratories, Inc. (NYSE: FRX ... announced today that Savella(TM) (milnacipran HCl), a selective serotonin and ... will be shipped to wholesalers on April 24th and will ... Savella was approved by the U.S. Food and Drug Administration ...
Cached Medicine News:Health News:All Persons Who Purchased or Acquired the Common Stock of Sunrise Senior Living, Inc. ('Sunrise') Between February 26, 2004 and July 28, 2006, Inclusive, and Were Damaged Thereby (The 'Class') 2Health News:All Persons Who Purchased or Acquired the Common Stock of Sunrise Senior Living, Inc. ('Sunrise') Between February 26, 2004 and July 28, 2006, Inclusive, and Were Damaged Thereby (The 'Class') 3Health News:Outgoing Nature Could Get You to 100 2Health News:Outgoing Nature Could Get You to 100 3Health News:IPC The Hospitalist Company, Inc. to Report First Quarter 2009 Financial Results 2Health News:PatientCentral Technologies, LLC and VerdaSee Solutions, Inc. Team Up With Congressional Staff in Washington, DC for Disaster Preparedness 2Health News:PatientCentral Technologies, LLC and VerdaSee Solutions, Inc. Team Up With Congressional Staff in Washington, DC for Disaster Preparedness 3Health News:PatientCentral Technologies, LLC and VerdaSee Solutions, Inc. Team Up With Congressional Staff in Washington, DC for Disaster Preparedness 4Health News:Poniard Announces Publication of Results of Picoplatin Phase 2 Study in Journal of Clinical Oncology 2Health News:Poniard Announces Publication of Results of Picoplatin Phase 2 Study in Journal of Clinical Oncology 3Health News:Poniard Announces Publication of Results of Picoplatin Phase 2 Study in Journal of Clinical Oncology 4Health News:Poniard Announces Publication of Results of Picoplatin Phase 2 Study in Journal of Clinical Oncology 5Health News:Forest Laboratories, Inc. and Cypress Bioscience, Inc. Announce Commercial Availability of Savella(TM) 2Health News:Forest Laboratories, Inc. and Cypress Bioscience, Inc. Announce Commercial Availability of Savella(TM) 3Health News:Forest Laboratories, Inc. and Cypress Bioscience, Inc. Announce Commercial Availability of Savella(TM) 4Health News:Forest Laboratories, Inc. and Cypress Bioscience, Inc. Announce Commercial Availability of Savella(TM) 5Health News:Forest Laboratories, Inc. and Cypress Bioscience, Inc. Announce Commercial Availability of Savella(TM) 6
... national reference laboratory and a worldwide leader ... offers an extensive test menu of highly ... and anatomic pathology. Owned by the University ... than half of the nation's university teaching ...
... a national reference laboratory and a worldwide ... ARUP offers an extensive test menu of ... clinical and anatomic pathology. Owned by the ... more than half of the nation's university ...
... national reference laboratory and a worldwide leader ... offers an extensive test menu of highly ... and anatomic pathology. Owned by the University ... than half of the nation's university teaching ...
... a national reference laboratory and a worldwide ... ARUP offers an extensive test menu of ... clinical and anatomic pathology. Owned by the ... more than half of the nation's university ...
Medicine Products: